XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Targeting Autism Therapeutics Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Source: NASDAQ.COM
- Acquisition Overview: XTL Biopharmaceuticals has agreed to acquire 85% of NeuroNOS for $1 million in cash and up to $32.5 million in milestone payments, representing 19.9% of XTL's issued share capital.
- Market Potential: With Autism Spectrum Disorder affecting approximately 1 in 31 children in the U.S., this acquisition positions XTL as a significant player in the rapidly expanding autism therapeutics market, likely driving future growth.
- Funding Support: The U.S. Department of Health and Human Services has allocated $50 million in new NIH funding for autism research initiatives, highlighting government commitment to the sector and enhancing XTL's market outlook.
- Clinical Development Milestones: The transaction includes up to $5.5 million in clinical development payments covering all phases from Phase 1 trials to FDA submission, ensuring financial backing for XTL throughout the product development process.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XAIR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XAIR
Wall Street analysts forecast XAIR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XAIR is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.270
Low
6.00
Averages
6.00
High
6.00
Current: 1.270
Low
6.00
Averages
6.00
High
6.00
About XAIR
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
XTL Biopharmaceuticals Acquires 85% of NeuroNOS for $1M and Up to $32.5M in Milestones
- Acquisition Details: XTL will acquire 85% of NeuroNOS for 19.9% of its issued share capital, $1 million in cash, and contingent milestone payments up to $32.5 million, marking a strategic move into autism and neuro-oncology therapeutics.
- Positive Market Reaction: Following XTL's announcement to acquire NeuroNOS, shares of Beyond Air (XAIR) surged 149%, while XTLB shares rose 51% at the time of writing, indicating strong market approval of the deal.
- Autism Treatment Platform: NeuroNOS's drug development platform focuses on addressing the molecular mechanisms of autism, contrasting with existing treatments based on behavioral symptoms, which is expected to provide XTL with new therapeutic avenues in autism and neuro-oncology.
- Enhanced Policy Support: The U.S. government has allocated $50 million in NIH funding for autism research, reflecting a heightened focus on new drug development, which may provide XTL with policy backing and financial support for future growth.
Continue Reading
Beyond Air (XAIR) Sells 85% of NeuroNOS for Up to $32.5 Million
- Transaction Details: Beyond Air has entered into an agreement with XTL Biopharmaceuticals to sell 85% of its subsidiary NeuroNOS, which includes 19.9% of XTL's shares, $1 million in cash, and up to $32.5 million in milestone payments, indicating a strategic move in the biopharmaceutical sector.
- Market Potential: This deal positions XTL to become a key player in the rapidly growing autism therapeutics market, addressing critical global healthcare needs, particularly for underserved patient populations, thus holding significant social value and commercial prospects.
- R&D Support: NeuroNOS focuses on autism and neuro-oncology treatments and holds FDA Orphan Drug Designations, providing market exclusivity and accelerated approval pathways, which are expected to yield up to $5.5 million in clinical development payments for Beyond Air, facilitating its R&D progress.
- Shareholder Value Enhancement: Beyond Air's CEO Steve Lisi stated that this transaction validates the scientific foundation of NeuroNOS and creates significant value for shareholders, as it is expected to drive the advancement of NeuroNOS's pipeline with dedicated resources and funding.
Continue Reading